Regulatory: PCAC Meeting to Decide Fate of Seven Peptides On July 23-24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will vote on whether to permit compounding pharmacies to produce seven popular peptides: BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax, and Epitalon. However, according to recent briefing documents published by the agency, FDA career scientists have pushed back against the approval of these compounds, determining there is inadequate evidence to support their safety or efficacy in humans. The reviewers specifically noted immunogenicity risks for injectable formulations and cited a lack of physical and chemical characterization for most of the substances on the docket. Legal & Enforcement: GLP-1 '503B' Exclusion With drug shortages easing, the FDA is taking sweeping steps to restrict the large-scale compounding of blockbuster GLP-1 weight-loss drugs. Coverage published this week by Stanford University highlighted the ongoing regulatory shift following the FDA's proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the '503B Bulks List.' This move effectively eliminates the legal pathway for large-scale outsourcing facilities to compound identical copies of these patented drugs. Additionally, the FDA has continued issuing warning letters to compounders making unsubstantiated 'generic equivalent' claims or utilizing unapproved salt forms. Market & Political Context The peptide market remains deeply divided. Some political figures have voiced support for expanding access to wellness peptides, even appointing peptide-friendly physicians to the PCAC. Conversely, mainstream pharmaceutical experts and FDA career staff warn of a 'gray market' populated by online vendors selling unproven freeze-dried powders under the guise of 'for research use only' (RUO). If the PCAC aligns with FDA scientists next week and votes against these seven peptides, industry analysts expect increased enforcement actions against both compounding pharmacies and online RUO vendors suspected of selling to consumers for human injection. Compliance Takeaway for RP Wellness For a U.S. research peptide supplier, this week’s developments emphasize the critical need to maintain a strict compliance boundary. As the FDA cracks down on 503B pharmacies and closely scrutinizes BPC-157, TB-500, and GLP-1 analogs, suppliers must ensure that all marketing, sales channels, and customer communications strictly reflect bona fide B2B laboratory research use, explicitly disclaiming human consumption or compounding applications.